AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29856509 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute compression hosiery
Number of subjects: 865
Study 29856509 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer bandaging
Number of subjects: 865
Study 29856509 — intervention group
Group type: COMPARATOR
Intervention: No compression
Number of subjects: 865
Study 29856773 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with poor insight (n = 68)
Number of subjects: 108
Study 29856824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral niclosamide 500mg TID
Number of subjects: 5
Study 29856824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral niclosamide 1000mg TID
Number of subjects: 5
Study 29856824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral niclosamide 1500mg TID
Number of subjects: 5
Study 29856824 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide (standard dose)
Number of subjects: 5
Study 29856824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral niclosamide (overall)
Number of subjects: 5
Study 29857090 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic therapy (infliximab, adalimumab, certolizumab, natalizumab, ustekinumab)
Number of subjects: 824
Study 29857090 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 824
Study 29857090 — intervention group
Group type: COMPARATOR
Intervention: Infants whose mothers received biologics, immunomodulators, or combination therapy
Number of subjects: 824
Study 29857145 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 1158
Study 29857145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1158
Study 29858106 — intervention group
Group type: EXPERIMENTAL
Intervention: H.E.L.P.-apheresis (2-6 treatments)
Number of subjects: 6
Study 29858106 — intervention group
Group type: EXPERIMENTAL
Intervention: H.E.L.P.-apheresis
Number of subjects: 6
Study 29858106 — intervention group
Group type: COMPARATOR
Intervention: Control group (<28 GW, n=6)
Number of subjects: 6
Study 29858382 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous biatrial contact mapping with 64 electrode catheters
Number of subjects: 14
Study 29858382 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanism of arrhythmia maintenance consistent with the multiple wavelet hypothesis
Number of subjects: 14
Study 29858465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence ≥100 steps/min
Number of subjects: 38
Study 29858465 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak 1-min cadence
Number of subjects: 38
Study 29858465 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak 30-min cadence
Number of subjects: 38
Study 29858465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mean daily cadences
Number of subjects: 38
Study 29858547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29859038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8-week group intervention)
Number of subjects: 110
Study 29859084 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of toothbrush and toothpaste at least once a day
Number of subjects: 39
Study 29859084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rinse during pregnancy
Number of subjects: 39
Study 29859084 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of dental care
Number of subjects: 39
Study 29859740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir (400 mg sofosbuvir, 100 mg velpatasvir, 100 mg voxilaprevir once daily for 12 weeks)
Number of subjects: 147
Study 29859740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir
Number of subjects: 147
Study 29859785 — intervention group
Group type: EXPERIMENTAL
Intervention: Elekta Clarity Autoscan system for ultrasound-based intrafraction motion estimation
Number of subjects: 16
Study 29859851 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib 135 mg/day for men and 90 mg/day for women (oral solution)
Number of subjects: 333
Study 29859908 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically healthy obesity
Number of subjects: 90257
Study 29859908 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically unhealthy normal weight
Number of subjects: 90257
Study 29859908 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically unhealthy overweight
Number of subjects: 90257
Study 29859908 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically unhealthy obesity
Number of subjects: 90257
Study 29859908 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintained metabolically healthy obesity
Number of subjects: 90257
Study 29859908 — intervention group
Group type: EXPERIMENTAL
Intervention: Converted to unhealthy phenotype (normal-weight)
Number of subjects: 90257
Study 29859908 — intervention group
Group type: EXPERIMENTAL
Intervention: Converted to unhealthy phenotype (obesity)
Number of subjects: 90257
Study 29859909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient preconception 25-hydroxyvitamin D (≥75 nmol/L)
Number of subjects: 1191
Study 29859909 — intervention group
Group type: COMPARATOR
Intervention: Insufficient preconception 25-hydroxyvitamin D (<75 nmol/L)
Number of subjects: 1191
Study 29859993 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c <70mmol/mol (<8.6%)
Number of subjects: 987
Study 29859993 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c [40-50) mmol/mol ([5.8-6.7) %)
Number of subjects: 987
Study 29859993 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c [50-70) mmol/mol ([6.7-8.6) %) or <40mmol/mol (<5.8%)
Number of subjects: 987
Study 29859993 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≥70mmol/mol (≥8.6%)
Number of subjects: 987
Study 29860039 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR4 polymorphisms (TLR4-Asp299Gly, TLR4-Thr399Ile)
Number of subjects: 224
Study 29860039 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR9-T1237C polymorphism
Number of subjects: 224
Study 29860039 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR4 polymorphisms
Number of subjects: 224
Study 29860938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg daily
Number of subjects: 258
Study 29861102 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional left atrial appendage closure (LAAC)
Number of subjects: 44
Study 29861390 — intervention group
Group type: EXPERIMENTAL
Intervention: High basal and low stimulated lipolysis at baseline
Number of subjects: 0
Study 29861390 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stimulated lipolysis
Number of subjects: 0
Study 29861609 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Screening for Esophageal Cancer (ESECC) trial
Number of subjects: 12085
Study 29861796 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of total soluble RAGE (sRAGE) and endogenous secretory (es)RAGE measured by duplicate ELISA
Number of subjects: 294
Study 29862011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild to moderate COPD subjects
Number of subjects: 0
Study 29862011 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic current smokers
Number of subjects: 0
Study 29862011 — intervention group
Group type: COMPARATOR
Intervention: Healthy former smokers
Number of subjects: 0
Study 29862011 — intervention group
Group type: COMPARATOR
Intervention: Healthy never-smokers
Number of subjects: 0
Study 29862011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild to moderate COPD
Number of subjects: 0
Study 29862030 — intervention group
Group type: EXPERIMENTAL
Intervention: EDIT management (elastance-directed intrapleural catheter)
Number of subjects: 0
Study 29862030 — intervention group
Group type: COMPARATOR
Intervention: Standard care (attempt at talc pleurodesis)
Number of subjects: 0
Study 29862031 — intervention group
Group type: EXPERIMENTAL
Intervention: HD+ bronchoscopy with i-scan image enhancement
Number of subjects: 107
Study 29862225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue cessation
Number of subjects: 92
Study 29862269 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants
Number of subjects: 0
Study 29862269 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional implants
Number of subjects: 0
Study 29862286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low torque group
Number of subjects: 75
Study 29862286 — intervention group
Group type: EXPERIMENTAL
Intervention: High torque group
Number of subjects: 75
Study 29862286 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium torque group
Number of subjects: 75
Study 29862437 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and rituximab with escalating doses of lenalidomide
Number of subjects: 45
Study 29862466 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (extended and continuous infusion)
Number of subjects: 50
Study 29862466 — intervention group
Group type: COMPARATOR
Intervention: Standard intermittent piperacillin dosing regimens
Number of subjects: 50
Study 29862506 — intervention group
Group type: EXPERIMENTAL
Intervention: OAMS framework integrated coaching
Number of subjects: 666
Study 29862656 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy silicone oil (Densiron-68™ HSO)
Number of subjects: 35
Study 29862656 — intervention group
Group type: COMPARATOR
Intervention: Standard silicone oil (PDMS)
Number of subjects: 35
Study 29863313 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29863388 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline on four consecutive days
Number of subjects: 40
Study 29863388 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 40
Study 29863899 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal step-down therapy with moderate-dose combination inhaled corticosteroids/long-acting β-agonists
Number of subjects: 0
Study 29863979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab (3 mg/kg every 2 weeks)
Number of subjects: 85
Study 29864044 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dorzolamide-timolol, administered as one drop twice daily for the duration of the study.
Number of subjects: 8
Study 29864089 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive pancreatoduodenectomy (MIPD)
Number of subjects: 729
Study 29864089 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic MIPD
Number of subjects: 729
Study 29864089 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted MIPD
Number of subjects: 729
Study 29865778 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pp65-specific ELISPOT results (< 11 spots/200,000 cells)
Number of subjects: 133
Study 29865778 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pp65-specific ELISPOT results (≥ 11 spots/200,000 cells)
Number of subjects: 133
Study 29865778 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pp65-specific ELISPOT assay results
Number of subjects: 133
Study 29865778 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 133
Study 29866196 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Paleolithic diet
Number of subjects: 0
Study 29866196 — intervention group
Group type: EXPERIMENTAL
Intervention: Low saturated fat diet
Number of subjects: 0
Study 29866196 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 0
Study 29866200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program for 4 weeks
Number of subjects: 45
Study 29866200 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SPPB-scores
Number of subjects: 45
Study 29866200 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in SPPB-scores
Number of subjects: 45
Study 29866202 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed transition interventions
Number of subjects: 1000
Study 29866202 — intervention group
Group type: EXPERIMENTAL
Intervention: Current service provision and new transition-related measures
Number of subjects: 1000
Study 29866202 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal outcomes for young people leaving CAMHS
Number of subjects: 1000
Study 29866202 — intervention group
Group type: EXPERIMENTAL
Intervention: Training modules for clinicians
Number of subjects: 1000
Study 29866202 — intervention group
Group type: EXPERIMENTAL
Intervention: Commissioning and policy guidelines for service providers
Number of subjects: 1000
Study 29866619 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vessel analysis combined with stenosis for ischemia
Number of subjects: 254
Study 29866619 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal LD-NCP evaluation
Number of subjects: 254
Study 29866619 — intervention group
Group type: COMPARATOR
Intervention: Stenosis alone
Number of subjects: 254
Study 29866628 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g Oral Glucose Tolerance Test (OGTT) in PD patients
Number of subjects: 50
Study 29866628 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (CT)
Number of subjects: 50
Study 29866789 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic (Winclove 612)
Number of subjects: 350
Study 29866789 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 350
Study 29866794 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of any pathogen
Number of subjects: 958
Study 29866794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrhinovirus pathogens
Number of subjects: 958
Study 29866794 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus
Number of subjects: 958
Study 29866794 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza
Number of subjects: 958
Study 29866794 — intervention group
Group type: EXPERIMENTAL
Intervention: Parainfluenza
Number of subjects: 958
Study 29867173 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 5025
Study 29867602 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine + ECT
Number of subjects: 15
Study 29867602 — intervention group
Group type: EXPERIMENTAL
Intervention: sequence of treatments
Number of subjects: 15
Study 29867602 — intervention group
Group type: COMPARATOR
Intervention: ketamine + sham ECT
Number of subjects: 15
Study 29867616 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29867646 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Reduction Program
Number of subjects: 0
Study 29867646 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 29867717 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-to-target pointing task in VR for individuals with stroke (mild and moderate)
Number of subjects: 67
Study 29867717 — intervention group
Group type: COMPARATOR
Intervention: Target-to-target pointing task in VR for healthy controls
Number of subjects: 67
Study 29867728 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP (6 months)
Number of subjects: 62
Study 29867728 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP (3 months) followed by active CPAP (6 months)
Number of subjects: 62
Study 29867923 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (aHSCT)
Number of subjects: 0
Study 29867923 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) cell reconstitution
Number of subjects: 0
Study 29867922 — intervention group
Group type: EXPERIMENTAL
Intervention: SV-BR-1-GM, a GM-CSF-secreting breast tumor cell line
Number of subjects: 1
Study 29867930 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug therapy (MDT)
Number of subjects: 0
Study 29868357 — intervention group
Group type: EXPERIMENTAL
Intervention: Summertime weight-gain prevention intervention
Number of subjects: 51
Study 29868357 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 51
Study 29868473 — intervention group
Group type: EXPERIMENTAL
Intervention: Triapine-cisplatin-radiation
Number of subjects: 0
Study 29868473 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-radiation
Number of subjects: 0
Study 29868792 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-vaccination expectation of side effects
Number of subjects: 270
Study 29868792 — intervention group
Group type: EXPERIMENTAL
Intervention: Media suggestions, NHS vaccination leaflet, health care workers' suggestions, uncertainty-related beliefs, perceived sensitivity to medicines, pessimism, and anxiety
Number of subjects: 270
Study 29868792 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effect perception
Number of subjects: 270
Study 29868913 — intervention group
Group type: EXPERIMENTAL
Intervention: Even-chain saturated fatty acids (SFAs) concentrations
Number of subjects: 2802
Study 29868913 — intervention group
Group type: EXPERIMENTAL
Intervention: Odd-chain saturated fatty acids (SFAs) concentrations
Number of subjects: 2802
Study 29868913 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid (16:0)
Number of subjects: 2802
Study 29868913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentadecanoic acid (15:0)
Number of subjects: 2802
Study 29868913 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptadecanoic acid (17:0)
Number of subjects: 2802
Study 29868913 — intervention group
Group type: EXPERIMENTAL
Intervention: High even-chain SFA concentrations and low odd-chain SFAs
Number of subjects: 2802
Study 29868913 — intervention group
Group type: EXPERIMENTAL
Intervention: Even-chain and odd-chain SFAs
Number of subjects: 2802
Study 29869084 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1591
Study 29869084 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1591
Study 29869107 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase ovarian stimulation (LPOS)
Number of subjects: 60
Study 29869107 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase ovarian stimulation (FPOS)
Number of subjects: 60
Study 29869523 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 (T2D with acute CF)
Number of subjects: 51
Study 29869523 — intervention group
Group type: COMPARATOR
Intervention: G2 (T2D with equivalent neuropathy)
Number of subjects: 51
Study 29869534 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal injection of rAAV2-CB-hRPE65
Number of subjects: 12
Study 29869835 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-CAD score (risk scoring system based on 10 independent risk factors)
Number of subjects: 14032
Study 29869835 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-CAD score
Number of subjects: 14032
Study 29869957 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema with interstitial features
Number of subjects: 8266
Study 29870382 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔHgb <1.0 g/dL
Number of subjects: 7608
Study 29870382 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔHgb ≥1.0 to <2.0 g/dL
Number of subjects: 7608
Study 29870382 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔHgb ≥2.0 to <3.0 g/dL
Number of subjects: 7608
Study 29870382 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔHgb ≥3.0 to <4.0 g/dL
Number of subjects: 7608
Study 29870382 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔHgb ≥4.0 g/dL
Number of subjects: 7608
Study 29870396 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Grade
Number of subjects: 355
Study 29870396 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainz Pain Stage
Number of subjects: 355
Study 29870396 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 355
Study 29870396 — intervention group
Group type: COMPARATOR
Intervention: Employees
Number of subjects: 355
Study 29871514 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffolds with human umbilical cord mesenchymal stem cells (MSCs)
Number of subjects: 2
Study 29871595 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth recommender system delivering tailored motivational health messages
Number of subjects: 0
Study 29871595 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth recommender system
Number of subjects: 0
Study 29871795 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal oocyte retrieval procedures
Number of subjects: 12615
Study 29871852 — intervention group
Group type: COMPARATOR
Intervention: Usual case management
Number of subjects: 432
Study 29871852 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual case management plus smartphone
Number of subjects: 432
Study 29871852 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual case management with a study-provided smartphone that is preloaded with an innovative case management app
Number of subjects: 432
Study 29871853 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based positive emotion skills intervention (MARIGOLD)
Number of subjects: 735
Study 29871853 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancement strategies (facilitator contact, online discussion board, virtual badges)
Number of subjects: 735
Study 29871940 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsta valve implantation
Number of subjects: 10
Study 29862011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate COPD patients
Number of subjects: 0
Study 29862011 — intervention group
Group type: COMPARATOR
Intervention: Currently smoking asymptomatic subjects
Number of subjects: 0
Study 29862011 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects that had never smoked
Number of subjects: 0
Study 29872570 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) lymphodepletion prior to CAR T-cell therapy
Number of subjects: 0
Study 29872570 — intervention group
Group type: COMPARATOR
Intervention: CAR T-cell therapy alone
Number of subjects: 0
Study 29873008 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 107
Study 29873679 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 508
Study 29873679 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 508
Study 29873682 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of control over eating (LOC) during pregnancy
Number of subjects: 11132
Study 29873682 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent LOC during pregnancy
Number of subjects: 11132
Study 29873682 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional LOC during pregnancy
Number of subjects: 11132
Study 29873682 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring of mothers with frequent LOC
Number of subjects: 11132